DiscoveryProbe™ FDA-approved Drug Library: High-Throughput, Mechanistic, and Translational Screening Resource

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 bioactive compounds approved by major agencies such as FDA, EMA, and PMDA, provided as stable 10 mM DMSO solutions. This resource empowers high-throughput screening (HTS) and high-content screening (HCS) for drug repositioning and mechanistic studies across disease models (contrasted here: deeper mechanistic focus). Its comprehensive coverage of protein targets—including receptor agonists/antagonists and enzyme inhibitors—enables rapid, reproducible identification of novel pharmacological interactions (see Guo et al., 2025). APExBIO provides validated stability for up to 24 months at -80°C, supporting reproducible and scalable research outcomes.

Biological Rationale

Drug discovery increasingly leverages libraries of well-characterized, approved compounds to accelerate repositioning and mechanistic insight. The DiscoveryProbe™ FDA-approved Drug Library contains 2,320 compounds with proven clinical safety, spanning diverse classes such as antineoplastics, antidiabetics, and statins. Each compound is selected for regulatory approval by agencies including the FDA, EMA, HMA, CFDA, and PMDA, or for pharmacopeial listing (product specifications). This diversity enables systematic interrogation of signaling pathways, disease models, and pharmacological mechanisms with minimized off-target or toxicological confounders. For example, targeting the thyrotropin receptor (TSHR) in thyroid eye disease has benefited from such high-content screens, with 2'-O-galloylhyperin identified as a promising antagonist via FDA-approved drug libraries (Guo et al., 2025). The library's format—10 mM in DMSO, available in microplates or 2D-barcoded tubes—allows direct integration into HTS and HCS workflows, supporting both small-scale and industrial-scale projects.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library encompasses compounds with well-defined mechanisms, including:

• Receptor agonists and antagonists (e.g., β-blockers, TSHR antagonists)
• Enzyme inhibitors (e.g., kinase, protease, and histone deacetylase inhibitors)
• Ion channel modulators (e.g., calcium or potassium channel blockers)
• Signal pathway regulators (e.g., CREB, cAMP modulators)

Each compound features documented structure–activity relationships, clinical pharmacokinetics, and regulatory approval data. For instance, doxorubicin and metformin represent mechanistically distinct agents—topoisomerase II inhibition and AMP-activated protein kinase activation, respectively—facilitating multi-parametric screening across oncology and metabolic disease models. The inclusion of compounds like 2'-O-galloylhyperin, identified via virtual screening as a TSHR antagonist, underscores the library's utility for both target discovery and validation (Guo et al., 2025).

Evidence & Benchmarks

• The library enabled SBVS identification of 2'-O-galloylhyperin as a TSHR antagonist, which reduced cAMP production in TED-OFs in a dose-dependent manner (5–50 μM) (Guo et al., 2025).
• 2'-O-galloylhyperin treatment led to significant downregulation of adipogenic markers and hyaluronan (HA) synthesis in orbital fibroblasts, confirming target engagement in a clinically relevant model (Guo et al., 2025).
• Validated library stability: 12 months at -20°C and 24 months at -80°C, as confirmed by APExBIO quality control protocols (product documentation).
• Automated HTS with the L1021 kit enabled rapid differentiation of signal pathway response profiles in cancer and neurodegenerative models (see: structure/mechanism update).
• Direct integration into multi-well plate formats allows parallel screening of >2,000 compounds per run, supporting both academic and pharmaceutical pipelines (previous coverage: workflow implementation).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is designed for:

• High-throughput screening (HTS) for drug repositioning across diverse indications.
• Pharmacological target identification and validation in disease-relevant models (contrast: this article extends with clinical benchmarks).
• Signal pathway regulation studies, enzyme inhibitor screening, and neurodegenerative disease drug discovery.
• Rapid screening in oncology, metabolic, infectious, and rare disease models.

Common Pitfalls or Misconceptions

• Not a substitute for de novo chemical libraries: The library covers approved compounds, not novel chemical space.
• Does not guarantee clinical efficacy in new indications: Repositioning hits require further validation in disease- or patient-specific models.
• Limited for irreversible or covalent target profiling: Most compounds are reversible binders.
• Not intended for direct in vivo dosing: Compounds are supplied in DMSO for in vitro/ex vivo workflows only.
• Assay compatibility required: Some compounds may interfere with fluorescence/absorbance-based readouts; controls are essential.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is provided as ready-to-use 10 mM DMSO solutions in formats including 96-well and deep-well plates, or 2D barcoded screw-top storage tubes. Solutions are stable for 12 months at -20°C and 24 months at -80°C. Shipping is on blue ice for evaluation samples and at room temperature or blue ice upon request for bulk formats. Researchers can directly transfer library aliquots to cell-based, biochemical, or phenotypic screens, minimizing pipetting error and compound degradation. High-content imaging and multi-parametric flow cytometry are commonly used downstream assays. The standardized format streamlines integration into automated liquid handling systems for robust, large-scale screening.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library by APExBIO sets a benchmark standard for high-throughput, mechanistic, and translational drug screening. Its comprehensive coverage of regulatory-approved, clinically characterized compounds enables fast, reproducible identification of repositioning opportunities and novel pharmacological targets across diverse disease domains. Ongoing integration with AI/ML-driven analytics, 3D tissue models, and organoid platforms will further enhance its translational impact, bridging bench and bedside innovation. For additional workflow, mechanistic, or translational perspectives, see our extended analyses on translational acceleration (this article provides new clinical data and updated stability guidance).